Åse Aulie Michelet has her education from ETH in Zurich and is Cand. pharm from the University of Oslo. Michelet has long experience from the pharmaceutical industry; Nycomed, Amersham and GE Healthcare. She has held leading positions in these companies within R&D, marketing and manufacturing. Åse Aulie Michelet has also been CEO in Marine Harvest ASA and Teres Medical Group AS. She has had many board appointments in Orkla, Yare, Cermaq, Photocure and Royal Greenland. She is currently Chairman of the Board at BI and SpinChip Diagnostics AS, and board member at Odfjell SE and Terveystalo OY.
Inven2's Board of Directors
Inger Sandlie is professor of molecular biology and deputy director of the Center for Immune Regulation, University of Oslo. She has a PhD from the University of Bergen and did postdocs at Johns Hopkins University, USA, and the Norwegian National Cancer Hospital. She heads an active research group and is co-inventor of more than 10 patents that describe the production and use of modified antibodies and albumin. Furthermore, she is co-founder of two biotechnology companies, Vaccibody A/S and Nextera A/S, and has an extensive research collaboration with Novozymes A/S. In 2011, she received the first innovation prize awarded by the University of Oslo.
Erlend B. Smeland is director of research, innovation and education at Oslo University Hospital and professor at the University of Oslo. He is a group leader at the Centre for Cancer Biomedicine at the University of Oslo. He has been Head of department at the Institute for Cancer Research at Oslo university Hospital and Head of Research in the South-Eastern Norway Regional Health Authority. Erlend B. Smeland is a member of the Board of Directors of the Norwegian Radium Hospital Research Foundation.
In 2004, Erlend B. Smeland received King Olav V’s Cancer Research Award.
Ragnhild A. Lothe is head of Department of Molecular Oncology and of the K.G. Jebsen Colorectal Cancer Research Centre at Oslo University Hospital. She is a professor in molecular genetics and co-director of the Centre for Cancer Biomedicine at University of Oslo. Her research group carries out research for improved risk stratification and novel treatment strategies for cancer patients. She is co-inventor of several active innovation projects and of 8 patents for cancer biomarkers. Lothe is chair of the board of the Centre for Molecular Medicine Norway - with EMBL partnership (European Molecular Biology Laboratory) and national member of the Advisory Council of the EACR (European Association for Cancer Research). Ragnhild A. Lothe received King Olav V’s Prize for Cancer Research 2007.
Per Morten Sandset is vice-rector and professor at the University of Oslo. His main responsibility is research and innovation with a special focus on the development of the life science area at the University. He holds an adjunct position at the Oslo University Hospital being a group leader at the Research Institute of Internal Medicine and the Department of Haematology. He is involved in basic and clinical studies related mainly to mechanisms of thrombosis and prophylaxis and treatment of venous thrombosis. He has been leader of the Haematological Research Laboratory, head of the Department of Haematology and assistant director of the Medical Division at Ullevål University Hospital (now part of Oslo University Hospital), and research director of the Division of cancer, surgery and transplantation at Oslo University Hospital. During 2015-17 he was director of research, innovation and education of the southeastern Norway health region, which is responsible for approximately 60% of the total research output of the Norwegian specialist health care.
Tom Pike is a life science industry professional holding board positions and other engagements related to the field. For many years he has worked to promote the health Industry in Norway, eg. as initiator and member of the Norwegian governmental HealthcareCare21 Strategy Council, contributing to the BioVerdi report, mentor in the UiO SPARK program, etc. He has over 30 years of experience in the health industry, including wiglobal responsibilities at Roche in Switzerland and as CEO of Roche Norway, Partner at the venture capital fund NeoMed and Chairman of the pharmaceutical industry association (LMI). For the past 13 years, the main focus has been on start-up companies in Norway and Sweden. He combines his board positions and consulting work with a part-time engagement at Oslo Metropolitan University working with innovation infrastructure. Tom Pike holds a B.Sc. Honors in pharmacology and has participated in a number of educational programs in business & administration, sales & marketing and finance.